Technical Reports on Medical Instruments Stocks -- Baxter, Skyline Medical, DENTSPLY SIRONA, and Hill-Rom

News provided by

Jan 26, 2017, 06:45 ET

NEW YORK, January 26, 2017 /PRNewswire/ --

The Medical Instruments and Supplies space is a mature and consolidating industry with relatively high profit margins, making it largely resilient during recessions. Companies in this category research, develop, and produce non-electronic medical, surgical, dental, and veterinary instruments and apparatus. This morning, Stock-Callers.com scans the performances of the following stocks: Baxter International Inc. (NYSE: BAX), Skyline Medical Inc. (NASDAQ: SKLN), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), and Hill-Rom Holdings Inc. (NYSE: HRC). Download the free research reports on these stocks today:

http://stock-callers.com/registration

Baxter

Shares in Deerfield, Illinois headquartered Baxter International Inc. rose 0.63%, ending Wednesday's trading session at $46.14. The stock recorded a trading volume of 2.66 million shares. The Company's shares have gained 4.48% in the last one month and 4.06% on an YTD basis. The stock is trading 1.70% and 0.98% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Baxter International, which provides a portfolio of renal and hospital products, have a Relative Strength Index (RSI) of 54.08.

On January 19^th, 2017, Renal Therapy Services, a global provider of kidney care services that is owned by Baxter International, announced that a continuous quality improvement program has reduced peritonitis by 65% over an eight-year period in 49 of its Renal Care Centers located in Colombia. The program is estimated to have prevented approximately 10,400 peritonitis episodes, saved approximately $200,000 per year, and helped achieve an infection rate that is significantly lower than the benchmark set by the International Society of Peritoneal Dialysis. See our free and comprehensive research report on BAX at:

http://stock-callers.com/registration/?symbol=BAX

Skyline Medical

Eagan, Minnesota-based Skyline Medical Inc.'s stock closed the day flat at $2.20 with a total trading volume of 178,952 shares. The Company's shares are trading 24.70% below their 50-day moving average. Shares of the Company, which manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the US, have an RSI of 34.47.

On January 19^th, 2017, Dawson James Securities, Inc., in conjunction with Skyline Medical, announced the closing of a registered direct offering of 1,750,000 units consisting of one share of common stock and 0.2 warrants for gross proceeds of $3,937,500. SKLN free research report PDF is just a click away at:

http://stock-callers.com/registration/?symbol=SKLN

DENTSPLY SIRONA

On Wednesday, shares in York, Pennsylvania headquartered DENTSPLY SIRONA Inc. recorded a trading volume of 1.75 million shares, which was higher than their three months average volume of 1.67 million shares. The stock ended the day 1.25% higher at $56.91. The Company's shares are trading below their 50-day moving average by 3.10%. Furthermore, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the US and internationally, have an RSI of 43.51. Sign up for your complimentary report on XRAY at:

http://stock-callers.com/registration/?symbol=XRAY

Hill-Rom

Chicago, Illinois headquartered Hill-Rom Holdings Inc.'s stock climbed 0.43%, finishing yesterday's session at $60.19 with a total trading volume of 525,582 shares. The Company's shares have advanced 6.53% in the last one month, 1.15% over the previous three months, and 7.21% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.19% and 10.23%, respectively. Additionally, shares of Hill-Rom Holdings, which operates as a medical technology company worldwide, have an RSI of 66.12.

On January 10^th, 2017, Hill-Rom Holdings announced that it has signed a definitive agreement to acquire Mortara Instrument, Inc., a privately held leader in diagnostic cardiology and patient monitoring solutions, technologies and devices, for $330 million in cash. Hill-Rom anticipates the structure of the acquisition will allow the Company to qualify for a significant tax benefit, which at a net present value of approximately $40 million reduces the effective purchase price to approximately $290 million.

On January 24^th, 2017, research firm Stifel initiated a 'Buy' rating on the Company's stock, with a target price of $70 per share. Register for free on Stock-Callers.com and download the latest research report on HRC at:

http://stock-callers.com/registration/?symbol=HRC

Stock Callers:

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

SC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: +44 330 808 3765

Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP